MedTrace Logo

The Role of Somatostatin in the Hemodynamics of the Hepatic Circulation in Patients Undergoing Liver Resection

NCT04010669 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-07-08

No results posted yet for this study

Summary

The purpose of the present clinical trial is to study the effect of somatostatin in the regulation of velocity and blood flow of the hepatic circulation in patients undergoing liver resection. The patients will be randomized in two groups: the study group will receive somatostatin and the control group will receive the placebo. In both groups, patients will undergo hepatectomy and directly postoperatively they will receive either somatostatin or placebo, depending on their randomization. The primary endpoint will be the increase or decrease of the velocity and the flow of the hepatic circulation estimated by ultrasonography compared to the same parameters when measured preoperatively.

Conditions

  • Portal Hypertension

Interventions

DRUG

Somatostatin

2 amp of somatostatin at 1000ml normal saline solution in continuous 24-hour infusion for 5 days

DRUG

Placebo

24 hours infusion of 1000ml Normal Saline solution 0.9%

Sponsors & Collaborators

  • Laikο General Hospital, Athens

    lead OTHER

Principal Investigators

  • Georgios C Sotiropoulos, MD, PhD · Assistant Professor of Surgery, Laiko Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2020-03-31
Completion
2020-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04010669 on ClinicalTrials.gov